Abstract
Objective
The aim of this study was to approach the relationship between the expression of human kallikrein 6 (hK6) in ovarian neoplasm and the clinicopathologic variables and prognosis for finding a new tumor marker for ovarian cancer.
Methods
Through immunohistochemistry to examine the expression of hK6 in 19 cases with benign, 11 cases with borderline and 45 cases with malignant ovarian neoplasms and statistically analyzed whether the expression of hK6 correlated with the clinicopathologic variables and prognosis in patients with ovarian cancer.
Results
The positive rate of hK6 in ovarian cancer tissues (60.0%) was significantly higher than that in the benign (15.8%) and borderline (27.3%) ovarian neoplasm tissues (P < 0.01). The expression of hK6 in low-grade ovarian cancer tissues was higher than that in high-grade (68.4% vs 14.3%; P < 0.05); hK6 in late-stage (stage III) was more frequently expressed than that in early-stage (stage I or II) (76.7% vs 26.7%; P < 0.01); and it significantly higher in ovarian carcinomas with lymph node metastases than those without lymph node metastases (77.8% vs 33.3%; P < 0.01 ); moreover, the expression of hK6 in the cancer tissues that the patients died or their pathogenetic condition recurred or their tumor metastasized within 3 years after surgery was higher (75.0%) than that in the cancer tissues that the pathogenetic condition of the patients was stable (42.9%; P < 0.05).
Conclusion
The expression of hK6 in ovarian cancer tissues was higher than that in the benign and borderline ovarian neoplasm tissues, and high hK6 expression correlated with late-stage, low-grade, node metastasis and poor prognosis of patients. hK6 could potentially be a novel tumor marker for ovarian cancer that can predict the prognosis of the patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clements JA, Willemsen NW, Myers SA, et al. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Criti Rev Clin Lab Sci, 2004, 41: 265–312.
Yousef GM, Borgono CA, White NM, et al. In silico analysis of the human kallikrein gene 6. Tumor Biol, 2004, 25: 282–289.
Ni X, Zhang W, Huang KC, et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer, 2004, 91: 725–731.
Yang YB, Xu W. Research progress in tumor markers for ovarian cancer. Foreign Med Sci (Chinese), 2004, 31: 229–232.
Petraki CD, Karavana VN, Pavlos T, et al. The spectrum of human Kallikrein 6 (Zyme/Protease M/Neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem, 2001, 49: 1431–1441.
Ghosh MC, Grass L, Soosaipillai A, et al. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol, 2004, 25: 193–199.
Hoffman BR, Katsaros D, Scorilas A, et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br J Cancer, 2002, 87: 763–771.
Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol, 2003, 21: 1035–1043.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hu, C., Zhang, F., Chen, K. et al. The relationship between the expression of hK6 in ovarian neoplasm and the clinicopathologic variables and prognosis. Chin. -Ger. J. Clin. Oncol. 9, 40–43 (2010). https://doi.org/10.1007/s10330-009-0177-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-009-0177-5